--Roche Holding aims to accelerate its anti-obesity drugs to compete with rivals Eli Lilly and Novo Nordisk after positive results of its obesity pill candidate in an early-stage clinical trial, its Chief Executive Thomas Schinecker told the Financial Times. --The Swiss pharma company executive said its weight-loss drugs could enter the market earlier than expected, potentially by 2028, the FT reports. --Schinecker said its $3-billion-plus purchase of Carmot Therapeutics could lead to around seven weight-loss treatments, according to the FT.Full story: https://on.ft.com/3SpRwDrWrite to Helena Smolak at helena.smolak@wsj.com(END) Dow Jones Newswires07-29-24 0206ET

Source: Wall Street Journal July 29, 2024 06:12 UTC